Dividend Aristocrats and Dividend Kings Get a Healthcare Tilt in 2026

The S and P 500 Dividend Aristocrats index requires 25 consecutive years of dividend increases plus inclusion in the S and P 500 plus a market cap minimum. The index has 67 members as of the January 2026 reconstitution. The Dividend Kings list, which is not an official S and P index but is widely tracked by investors, requires 50 consecutive years of dividend increases regardless of S and P 500 membership. The 2026 Kings count stands at 53 companies. Both lists are powerful screens for investors who want long-duration cash flow rather than total return chasing.

Healthcare and consumer staples dominate both lists. Becton Dickinson hit the 25-year mark in February with its quarterly increase from $1.04 to $1.10. The medical device maker joined Aristocrats at the next reconstitution. Cintas, the uniform rental business, extended its streak to 41 years and remains on the Aristocrats list. Lowe's was promoted to a Dividend King in early 2026 after announcing its 50th consecutive annual increase. Procter and Gamble extended its streak to 70 years, the longest active record on the Kings list.

Performance through Q1 2026 favored the King and Aristocrat group versus the broader market. The ProShares S and P 500 Dividend Aristocrats ETF, ticker NOBL, returned 6.4 percent year to date through April 28 versus 4.1 percent for the S and P 500. The Vanguard Dividend Appreciation ETF, ticker VIG, with a less stringent 10-year increase requirement returned 5.7 percent. The Schwab US Dividend Equity ETF, ticker SCHD, returned 5.2 percent. Defensive sector tilts in healthcare and consumer staples drove the relative strength as growth and technology underperformed.

Yield levels remain modest. NOBL trades at a 30-day SEC yield of 2.27 percent. SCHD sits at 3.71 percent. The S and P 500 broadly yields 1.31 percent. The 10-year Treasury yields 4.30 percent. The yield gap between high quality dividend equity and government bonds is the narrowest since 2010, which means investors holding dividend names need to be there for the dividend growth profile rather than the current yield. The historical dividend growth rate for Aristocrats has been 8.2 percent compounded over 20 years.

Healthcare exposure inside Aristocrats includes Johnson and Johnson, AbbVie, Medtronic, Becton Dickinson, Stryker, Cardinal Health, and CVS Health. Johnson and Johnson extended its streak to 64 years with a 4.8 percent hike announced in April. AbbVie raised its quarterly dividend 5.5 percent in October 2025 to bring annual payout to $6.56 per share. Medtronic hit its 48th year of consecutive raises in May 2025 and is on track to join Kings in 2027. Stryker raised by 4.4 percent in December 2025 to begin its 33rd year.

Consumer staples representation is heavy. Procter and Gamble at 70 years. Coca-Cola at 64 years and 4.6 percent latest hike. PepsiCo at 54 years and 5.0 percent hike. Colgate Palmolive at 63 years. Kimberly Clark at 54 years. Hormel at 60 years. Walmart at 53 years and a 13 percent hike announced in February for fiscal 2026, the largest single-year increase in the company's history. Costco is not on the Kings list because of irregular special dividends, though the regular dividend has compounded at 13 percent over 20 years.

Industrials and financials offer balance. Illinois Tool Works has 62 years of increases. Roper Technologies has 33 years. Genuine Parts has 70 years tied for the longest active streak with Procter and Gamble. Cintas has 41 years. Emerson Electric has 69 years. Aflac has 43 years. Chubb has 33 years. Nordson has 62 years. Atmos Energy has 42 years. Black Hills Corporation has 56 years. The breadth across sectors makes Aristocrats and Kings useful for portfolio construction beyond a single sector concentration.

The risk in dividend strategies is that companies cut. Walgreens Boots Alliance was cut from the Aristocrats list in January 2024 after slashing its dividend 47 percent. AT and T was removed from the Aristocrats list in 2022 after spinning off Warner Media and resetting its dividend lower. The list cleansing functions correctly when an underlying business deteriorates. Investors should not assume that Aristocrat or King status is permanent. The screens are quality filters, not safety guarantees.

For 2026 portfolio construction, the practical move is to use NOBL, VIG, or SCHD as a core defensive holding and complement with individual names where conviction is high. Lowe's at 12.4 times forward earnings and 2.4 percent yield offers value with the Kings boost. Procter and Gamble at 24 times forward and 2.7 percent yield is fully priced. AbbVie at 14 times forward and 3.7 percent yield is the most attractive value name in the healthcare bucket. Johnson and Johnson at 16 times forward and 3.1 percent yield is the steady compounder. None of these will produce 30 percent annual returns. All of them will pay you to hold them while compounding through whatever the next decade brings.